LON:SUMM - Summit Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 23.98 +0.48 (+2.04 %)
(As of 01/21/2019 05:37 AM ET)
Previous CloseGBX 23.50
Today's RangeGBX 23.98 - GBX 23.98
52-Week RangeGBX 140 - GBX 269.70
Volume158 shs
Average Volume34,608 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). The company's lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials. It has strategic alliance with the University of Oxford to develop utrophin modulators. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.

Receive SUMM News and Ratings via Email

Sign-up to receive the latest news and ratings for SUMM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drugs - Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+44-1235-443939

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees76
OptionableNot Optionable

Summit Therapeutics (LON:SUMM) Frequently Asked Questions

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SUMM."

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics PLC (LON:SUMM) issued its earnings results on Tuesday, December, 11th. The company reported ($10.00) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($8.00) by $2.00. View Summit Therapeutics' Earnings History.

Has Summit Therapeutics been receiving favorable news coverage?

News headlines about SUMM stock have been trending somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Summit Therapeutics earned a news impact score of -1.4 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term.

Who are some of Summit Therapeutics' key competitors?

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the folowing people:
  • Mr. Glyn O. Edwards, CEO & Exec. Director (Age 63)
  • Mr. Erik Ostrowski, Chief Financial Officer (Age 46)
  • Prof. David Roblin, COO, Chief Medical Officer and Pres of R&D (Age 53)
  • Prof. Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 69)
  • Ms. Michelle Avery, Director of Investor Relations

How do I buy shares of Summit Therapeutics?

Shares of SUMM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Summit Therapeutics' stock price today?

One share of SUMM stock can currently be purchased for approximately GBX 23.98.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is http://www.summitplc.com/.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136A Eastern Avenue, ABINGDON, OX14 4SB, United Kingdom. The company can be reached via phone at +44-1235-443939.


MarketBeat Community Rating for Summit Therapeutics (LON SUMM)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  212 (Vote Underperform)
Total Votes:  354
MarketBeat's community ratings are surveys of what our community members think about Summit Therapeutics and other stocks. Vote "Outperform" if you believe SUMM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUMM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Intrinsic Value

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel